Discovery of Novel HDAC8 Inhibitors Through Shape-Based Virtual Screening: Experimental Validation and Characterization of a Promising Quinoline-Based Hit Scaffold
4 affiliations
- 1Dipartimento di Scienze della Salute, Università “Magna Græcia” di Catanzaro, Campus Universitario “S. Venuta”, Viale Europa, 88100 Catanzaro, Italy
- 2Associazione CRISEA—Centro di Ricerca e Servizi Avanzati per l’Innovazione Rurale, Località Condoleo, 88055 Belcastro, Italy
- 3BioLab, Instituto Universitario de Bio-Orgánica “Antonio González”, Universidad de la Laguna, C/Astrofísico Francisco Sánchez 2, 38206 La Laguna, Spain
- 4Institute of Biological and Chemical Systems—Functional Molecular Systems, Karlsruhe Institute of Technology (KIT), 76344 Eggenstein-Leopoldshafen, Germany
Abstract
Histone deacetylase 8 (HDAC8) is overexpressed in several solid tumors and, unlike other Class I HDACs, functions independently of large corepressor complexes, making it an attractive target for structure-based drug design. Here, we aimed to identify novel natural compounds capable of targeting the human HDAC8 catalytic site. A library of 307,814 natural products from ZINC15 was screened by shape-based virtual screening using five structurally diverse co-crystallized HDAC8 ligands as templates, followed by molecular docking and Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) binding free energy calculations. Seven commercially available hits were selected for enzymatic validation, leading to the identification of 4-((7-methoxyquinolin-4-yl)amino)benzamide (ZINC000054202375, compound 2) as a promising HDAC8 inhibitor. In vitro antiproliferative assays across multiple human solid tumor cell lines demonstrated significant growth inhibition by compound 2, further supported by colony formation assays. Mechanistic studies using label-free live-cell imaging, Annexin V staining, DAPI (4′,6-diamidino-2-phenylindole) nuclear morphology, and DCFDA (2′,7′-dichlorodihydrofluorescein diacetate) assays revealed membrane blebbing, mitotic failure, increased reactive oxygen species, and nuclear fragmentation, consistent with apoptosis induction. Finally, 1 μs molecular dynamics simulations supported the formation of a persistent ligand–receptor interaction network within the HDAC8 catalytic pocket. Overall, compound 2 represents a promising non-hydroxamate hit scaffold with promising HDAC8 inhibitory activity, serving as a starting point for the development of novel HDAC-targeted anticancer agents.
Related
- Prospective discovery of LasB inhibitors by integrating generative design, free energy ranking, and experimental validation
- Function-based OBOC screening for the direct discovery of potent protein-protein interaction inhibitors.
- Discovery of natural flavanones as potential PRMT4 inhibitors with antiproliferative activity against colorectal cancer cells
- Kinetic Target-Guided Discovery of Selective Nanomolar Hydroxamic Acid–Based Inhibitors of Pseudomonas aeruginosa Elastase LasB
- A Proximity-Driven Functional Screening Platform for the Discovery of Noninhibitory USP7 Ligand Enabling Targeted Protein Stabilization
BibTeX
@article{gargano2026discovery,
title = {{Discovery of Novel HDAC8 Inhibitors Through Shape-Based Virtual Screening: Experimental Validation and Characterization of a Promising Quinoline-Based Hit Scaffold}},
author = {Adriana Gargano and Aday González-Bakker and Adrián Puerta and Valentina Maggisano and Stefania Bulotta and Roberta Rocca and José M. Padrón and Stefano Alcaro},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27219557},
url = {https://www.mdpi.com/1422-0067/27/21/9557},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Discovery of Novel HDAC8 Inhibitors Through Shape-Based Virtual Screening: Experimental Validation and Characterization of a Promising Quinoline-Based Hit Scaffold
AU - Adriana Gargano
AU - Aday González-Bakker
AU - Adrián Puerta
AU - Valentina Maggisano
AU - Stefania Bulotta
AU - Roberta Rocca
AU - José M. Padrón
AU - Stefano Alcaro
PY - 2026
DA - 2026/10/26
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27219557
UR - https://www.mdpi.com/1422-0067/27/21/9557
AB - Histone deacetylase 8 (HDAC8) is overexpressed in several solid tumors and, unlike other Class I HDACs, functions independently of large corepressor complexes, making it an attractive target for structure-based drug design. Here, we aimed to identify novel natural compounds capable of targeting the human HDAC8 catalytic site. A library of 307,814 natural products from ZINC15 was screened by shape-based virtual screening using five structurally diverse co-crystallized HDAC8 ligands as templates, followed by molecular docking and Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) binding free energy calculations. Seven commercially available hits were selected for enzymatic validation, leading to the identification of 4-((7-methoxyquinolin-4-yl)amino)benzamide (ZINC000054202375, compound 2) as a promising HDAC8 inhibitor. In vitro antiproliferative assays across multiple human solid tumor cell lines demonstrated significant growth inhibition by compound 2, further supported by colony formation assays. Mechanistic studies using label-free live-cell imaging, Annexin V staining, DAPI (4′,6-diamidino-2-phenylindole) nuclear morphology, and DCFDA (2′,7′-dichlorodihydrofluorescein diacetate) assays revealed membrane blebbing, mitotic failure, increased reactive oxygen species, and nuclear fragmentation, consistent with apoptosis induction. Finally, 1 μs molecular dynamics simulations supported the formation of a persistent ligand–receptor interaction network within the HDAC8 catalytic pocket. Overall, compound 2 represents a promising non-hydroxamate hit scaffold with promising HDAC8 inhibitory activity, serving as a starting point for the development of novel HDAC-targeted anticancer agents.
SN - 1422-0067
ER -